USFDA classifies inspection of Lupin’s Tarapur facility as OAI

13 Jan 2020 Evaluate

Lupin has received a communication from the USFDA classifying the inspection conducted at its Toropur manufacturing (API) facility between September 16-20, 2019, as Official Action Indicated (OAI). The inspection at the Toropur facility had closed with three observations. The company is in the process of sending further updates of its corrective actions to the USFDA and is hopeful of a positive outcome.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×